Sightera Biosciences announced €3 million in pre-seed funding to expand its platform and oncology asset portfolio, with lead program SIGHT-001 remaining in focus. The company said the money will support extending its AI discovery capabilities and advancing additional programs identified through its computational pipeline. The round underscores continued early-stage investor interest in AI-driven discovery companies, particularly those with oncology programs positioned as near-term candidates for further development. The pre-seed allocation also signals a push to grow both the technical platform and the breadth of assets rather than concentrating solely on one molecule.